R Vongpromek1, S Bos1, G-J R Ten Kate2, R Yahya1, A J M Verhoeven1, P J de Feyter2,3, F Kronenberg4, J E Roeters van Lennep1, E J G Sijbrands1, M T Mulder1. 1. Division of Pharmacology Vascular and Metabolic Diseases, Department of Internal Medicine, Rotterdam, The Netherlands. 2. Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Division of Genetic Epidemiology, Department of Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Abstract
OBJECTIVES: Lipoprotein(a) [Lp(a)] is an independent risk factor for aortic valve stenosis and aortic valve calcification (AVC) in the general population. In this study, we determined the association between AVC and both plasma Lp(a) levels and apolipoprotein(a) [apo(a)] kringle IV repeat polymorphisms in asymptomatic statin-treated patients with heterozygous familial hypercholesterolaemia (FH). METHODS: A total of 129 asymptomatic heterozygous FH patients (age 40-69 years) were included in this study. AVC was detected using computed tomography scanning. Lp(a) concentration and apo(a) kringle IV repeat number were measured using immunoturbidimetry and immunoblotting, respectively. Univariate and multivariate logistic regression were used to assess the association between Lp(a) concentration and the presence of AVC. RESULTS: Aortic valve calcification was present in 38.2% of patients, including three with extensive AVC (>400 Agatston units). Lp(a) concentration was significantly correlated with gender, number of apo(a) kringle IV repeats and the presence and severity of AVC, but not with coronary artery calcification (CAC). AVC was significantly associated with plasma Lp(a) level, age, body mass index, blood pressure, duration of statin use, cholesterol-year score and CAC score. After adjustment for all significant covariables, plasma Lp(a) concentration remained a significant predictor of AVC, with an odds ratio per 10-mg dL(-1) increase in Lp(a) concentration of 1.11 (95% confidence interval 1.01-1.20, P = 0.03). CONCLUSION: In asymptomatic statin-treated FH patients, plasma Lp(a) concentration is an independent risk indicator for AVC.
OBJECTIVES:Lipoprotein(a) [Lp(a)] is an independent risk factor for aortic valve stenosis and aortic valve calcification (AVC) in the general population. In this study, we determined the association between AVC and both plasma Lp(a) levels and apolipoprotein(a) [apo(a)] kringle IV repeat polymorphisms in asymptomatic statin-treated patients with heterozygous familial hypercholesterolaemia (FH). METHODS: A total of 129 asymptomatic heterozygous FHpatients (age 40-69 years) were included in this study. AVC was detected using computed tomography scanning. Lp(a) concentration and apo(a) kringle IV repeat number were measured using immunoturbidimetry and immunoblotting, respectively. Univariate and multivariate logistic regression were used to assess the association between Lp(a) concentration and the presence of AVC. RESULTS:Aortic valve calcification was present in 38.2% of patients, including three with extensive AVC (>400 Agatston units). Lp(a) concentration was significantly correlated with gender, number of apo(a) kringle IV repeats and the presence and severity of AVC, but not with coronary artery calcification (CAC). AVC was significantly associated with plasma Lp(a) level, age, body mass index, blood pressure, duration of statin use, cholesterol-year score and CAC score. After adjustment for all significant covariables, plasma Lp(a) concentration remained a significant predictor of AVC, with an odds ratio per 10-mg dL(-1) increase in Lp(a) concentration of 1.11 (95% confidence interval 1.01-1.20, P = 0.03). CONCLUSION: In asymptomatic statin-treated FHpatients, plasma Lp(a) concentration is an independent risk indicator for AVC.
Authors: Nicolas Perrot; Sébastien Thériault; Christian Dina; Hao Yu Chen; S Matthijs Boekholdt; Sidwell Rigade; Audrey-Anne Després; Anthony Poulin; Romain Capoulade; Thierry Le Tourneau; David Messika-Zeitoun; Mikaël Trottier; Michel Tessier; Jean Guimond; Maxime Nadeau; James C Engert; Kay-Tee Khaw; Nicholas J Wareham; Marc R Dweck; Patrick Mathieu; Philippe Pibarot; Jean-Jacques Schott; George Thanassoulis; Marie-Annick Clavel; Yohan Bossé; Benoit J Arsenault Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu Journal: J Am Coll Cardiol Date: 2018-01-16 Impact factor: 24.094
Authors: Jing Cao; Brian T Steffen; Matthew Budoff; Wendy S Post; George Thanassoulis; Bryan Kestenbaum; Joseph P McConnell; Russell Warnick; Weihua Guan; Michael Y Tsai Journal: Arterioscler Thromb Vasc Biol Date: 2016-03-03 Impact factor: 8.311